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OBJECTIVE The objective of this study was to evaluate the American College of Cardiology/American
Heart Association (ACC/AHA) guidelines for exercise testing (EXT) after successful
coronary revascularization (CR) using the Bypass Angioplasty Revascularization Investigation
experience.
BACKGROUND The ACC/AHA guidelines state that EXT within three years of successful CR is not useful.
METHODS The 1,678 patients randomized to CR by either angioplasty or bypass surgery were required
to take symptom-limited treadmill tests one, three and five years after revascularization.
RESULTS Patients who took the test at each specified time had a much lower subsequent two-year
mortality than those who did not (1.9% vs. 9.4%, 3.5% vs. 12.6% and 3.3% vs. 11.0% at one,
three and five years, respectively, after CR [p , 0.0001 for each]). Exercise parameters at the
one- and three-year test did not improve a multivariable model of survival after including
clinical parameters. Exercising to Bruce stage 3 or generating a Duke score .26 were
independently predictive of two-year survival after the five-year test. ST depression on the
one-year test was associated with more revascularizations (relative risk 5 1.6; p , 0.001).
CONCLUSIONS Patients with stable multivessel coronary disease who took a protocol-mandated exercise test
at one, three and five years after revascularization were at low risk for mortality in the two
years subsequent to each test. Exercise parameters did not improve prediction of mortality
in the two years after the one- and three-year tests. The ACC/AHA guidelines on
exercise testing after CR (no value for routine testing in stable patients for three years
after revascularization) are supported by these results. (J Am Coll Cardiol 2001;38:
136 – 42) © 2001 by the American College of Cardiology
Routine stress testing in asymptomatic patients for three
years after successful coronary revascularization (CR) is
considered a class III indication (of no value) by the current
American College of Cardiology/American Heart Associa-
tion (ACC/AHA) exercise guidelines unless special ana-
tomical situations are present (1,2). Noninvasive testing has
been used in an attempt to discover asymptomatic occur-
rence of restenosis or conduit failure (1,3–7). This strategy
assumes that high-grade stenoses detected by noninvasive
tests require revascularization even if asymptomatic.
The Bypass Angioplasty Revascularization Investigation
(BARI) is an ongoing randomized trial comparing an initial
strategy of surgical to percutaneous revascularization on
mortality and recurrent infarction in patients with multives-
sel coronary artery disease (CAD) (8). The protocol re-
quired treadmill tests (EXTs) periodically after revascular-
ization. The goal of this study was to assess the ability of the
protocol-mandated EXTs to predict new cardiac events in
this population of stable patients with revascularized mul-
tivessel CAD.
METHODS
The details of the BARI protocol and seven-year survival
results have been published (8). To be eligible for the BARI,
multivessel CAD with clinically severe angina or ischemia
requiring revascularization and suitable for both percutane-
ous transluminal coronary angioplasty (PTCA) and coro-
nary bypass graft revascularization (CABG) was required.
Between August 1988 and August 1991, 1,829 patients
from 20 centers in North America were enrolled in the
study. The average age of patients at baseline was 61.5 years;
27% were women; 64% had unstable angina; 41% had
triple-vessel disease; 9% had congestive heart failure, and
19% had diabetes treated with either oral hypoglycemics or
insulin.
Exercise protocol. A symptom-limited treadmill test was
mandated one, three and five years after the index revascu-
larization procedure. The Bruce protocol was utilized for
most patients. Exercise electrocardiograms (ECGs) were
interpreted at the Core ECG Laboratory (CEL) in addition
to the local site. ST segment horizontal depression of
0.1 mV or more or upsloping with 1.5 mm depression 0.08 s
after the J point was required for a positive result (1). The
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Duke prognostic score, which incorporates exercise time,
development of angina and ST displacement was calculated
using the CEL ST analysis (9).
Follow-up. Patients were followed for a minimum of five
years after the one-year exercise test. Patients were con-
tacted annually. Mortality from all causes was the primary
end point. New cardiac events or mortality were timed from
the date of the EXT.
An independent committee assessed causes of death. A
Q-wave myocardial infarction (MI) was defined by new
persistent Q-waves or left bundle branch block with abnor-
mal enzymes.
Statistics. Data from patients treated with either PTCA or
CABG were combined. However, treatment allocation was
included in all multivariate analyses (8). Kaplan-Meier
survival curves were constructed and compared using the
log-rank test. Multivariable Cox models adding exercise
variables to other clinical variables previously determined to
predict events were constructed for the end points of
survival, survival free of Q-wave MI and subsequent revas-
cularization.
RESULTS
Of the 1,698 patients eligible to take the EXT one-year
after CR, 310 (18%) patients did not take it. At three years,
1,632 patients were eligible, and 424 (26%) did not take the
exercise test; at five years, 1,521 were eligible, and 474
(31%) did not take the exercise test. Demographics of the
patients at the time of the one-year test are seen in Table 1.
As expected, there was more comorbidity in the nonexer-
cisers. Treatment allocations were similar in the two groups.
Only 9% developed angina during the test, consistent with
the “protocol-not symptom driven” indication for the test.
No relationship was seen between reason for not exercising
(patient refusal, orthopedic limitation, peripheral vascular
disease and other) and survival, but there was a suggestion
that orthopedic limitation decreased five-year survival
(66.7% vs. 74.1%).
Nonexercisers had a 3.9% mortality rate in the year after
the scheduled test and 25.9% mortality after five years. This
compared with the 0.4% one-year mortality (relative risk
[RR] 5 9.2, p , 0.0001) and the 8.1% five-year mortality
in the group who did take the test. Within all subgroups
considered, the exercising patients had a better five-year
survival than nonexercising patients (Fig. 1). Nonexercisers
also had a higher combined rate of death or Q-wave
infarction than did the exercising patients (2.9% vs. 1.0% at
one year and 18.0% vs. 6.8% at five years). The nonexercis-
ers underwent more revascularizations in the first year after
the test (8% vs. 4%, p , 0.001). However, by the fifth year,
the cumulative rate was similar (18.6% vs. 16.5%, respec-
tively).
We evaluated survival for the two years after each of the
scheduled tests. The risk of two-year mortality in those who
did not take the EXT ranged from 9.4% after the one-year
test to 12.6% and 11.0% after the three and five year tests,
respectively. This compares with a two-year mortality of
1.9%, 3.5% and 3.3%, respectively, for the EXT takers
(Tables 2 and 3). The results for combined mortality or MI
show a similar difference (11.9% vs. 3.6%, multivariate
RR 5 2.86, p , 0.0001) for the two years after the one-year
test, for example.
The BARI trial has shown a difference in seven-year
mortality between treated diabetics who received PTCA as
compared with those receiving CABG (8). It was found that
73% of the CABG patients with diabetes and 71% of the
PTCA patients with diabetes performed the one-year EXT.
The five-year Kaplan Meier survival estimates for patients
with diabetes were 70.0% for the nonexercising CABG
patients compared with 47.6% in the nonexercising PTCA
patients with diabetes (p 5 0.0098) and 88.9% vs. 79.2% for
the patients who could exercise (p 5 0.0273), respectively
(Fig. 2). The corresponding estimates for patients without
treated diabetes were 80.2% vs. 80.3% for the nonexercising
Abbreviations and Acronyms
ACC/AHA 5 American College of
Cardiology/American Heart Association
BARI 5 Bypass Angioplasty Revascularization
Investigation
CABG 5 coronary artery bypass grafting
CAD 5 coronary artery disease
CEL 5 Core Electrocardiographic Laboratory
CR 5 coronary revascularization
ECG 5 electrocardiogram
EXT 5 exercise test
MI 5 myocardial infarction
PTCA 5 percutaneous transluminal coronary
angioplasty
RR 5 relative risk
Table 1. Demographics of the Patients Who Did and Did Not
Take the EXT at One Year
No
EXT
n 5 310
EXT
n 5 1,388 p Value
Mean age (yr) 63.3 60.7 , 0.01
Female gender 36% 25% , 0.01
Caucasian race 88% 91%
More than high school education 23% 30% , 0.01
Cerebrovascular disease/TIA 9% 5% , 0.01
Carotid artery surgery 3% 1% , 0.05
Lower extremity vascular disease 15% 7% , 0.01
Additional peripheral vascular disease 27% 13% , 0.01
COPD 9% 5% , 0.01
Creatinine .1.5 mg/dl 4% 2% , 0.01
Treated diabetes 28% 16% , 0.01
History of myocardial infarction 56% 54%
History of congestive heart failure 17% 6% , 0.01
History of hypertension 57% 46% , 0.01
Current smoker 31% 25% , 0.01
Abnormal left ventricular function 23% 19%
COPD 5 chronic obstructive pulmonary disease; EXT 5 exercise test; TIA 5
transient ischemic attack.
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patients and 93.1% compared with 93.6% for the patients
who exercised. All multivariate analyses were corrected for
the diabetes.
Relationship between EXT parameters and mortality
after each exercise test. The independent contribution of
exercise parameters to multivariable models for survival and
Figure 1. Subgroup analyses-risk of mortality related to taking of the exercise test (EXT). Five-year estimated survival rates for important patient subgroups.
The 99% confidence intervals (CI) of the difference between the five-year survival for patients who took the EXT and those who did not are shown. CHF 5
congestive heart failure; PVD 5 peripheral vascular disease.
Table 2. Mortality Rate in Patients for the Two Years After the One-, Three-, and Five-Year
Tests Based on Whether the Test Was Taken
No EXT EXT RR
n KM% n KM% Univariate Multivariate*
1-year EXT 310 9.4 1,388 1.9† 5.78† 4.58†
3-year EXT 424 12.6 1,208 3.5† 3.61† 2.79†
5-year EXT 472 11.0 1,049 3.3† 2.74† 2.29†
*Model includes congestive heart failure, age, peripheral vascular disease, education, renal dysfunction, treatment, diabetic status;
†p , 0.0001.
EXT 5 exercise test; KM 5 Kaplan-Meier estimate; RR 5 relative risk.
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survival free of MI was evaluated for the two years after each
test (Tables 4 and 5). The addition of exercise parameters
did not improve the models for survival or survival free of
infarction after the one and three year exercise tests.
Exercise duration was independently associated with de-
creased survival for two years after the five-year test (RR 5
0.42, p 5 0.0069) and was independently associated with
decreased survival free of MI for the two years after the
three-year test (RR 5 0.51, p 5 0.0372).
The CEL was able to evaluate the ST segment in 1,322
of the 1,388 exercising patients. ST depression, interpreted
at either site, was not related to subsequent infarction-free
survival. However, ST segment depression diagnosed at the
clinical site was strongly associated with revascularization
procedures five years after the one-year test (RR 5 1.6, p ,
0.001 compared with RR 5 1.22, p 5 0.16, for the CEL
measurements).
Twenty-eight patients (2%) underwent revascularization
within three months of the EXT. Of the 255 patients with
symptoms of angina before the test, 17 (6.7%) were revas-
cularized within three months compared with 11 of the
1,132 patients (1%) who did not report symptoms of angina.
Of the 11, seven had a negative EXT (no ST depression and
no angina during the test). Thus, of the 28 patients who
were revascularized within three months of the EXT, only
four (0.3% of the total patients) might be construed to be
revascularized only as result of ischemia documented on an
EXT (Table 6).
Long-term (five-year) mortality was also evaluated after
the one-year test. Exercising to Bruce stage 3, heart rate
.85% and Duke Score .26 were associated with an
improved five-years survival, but only Bruce Stage 3 was an
independent predictor of survival on the multivariate anal-
ysis (RR 5 0.69, p 5 0.04) (Fig. 3).
DISCUSSION
Coronary atherosclerosis is a progressive disease, and, there-
fore, even after a successful revascularization, recurrent
cardiac events are to be expected. In the first 12 to 18
months after revascularization, these events are more com-
mon in patients after PTCA than after CABG (8,10,11).
After 18 months, the number of events (primarily recur-
rence of angina) stabilizes and is similar for patients under-
going either procedure (8).
Additional prognostic information from the EXT param-
eters. The prognostic value of the results of the EXT for
survival or survival free of new Q-wave infarction in this
largely stabilized and asymptomatic population of patients
after revascularization was limited. Specific exercise param-
eters were disappointingly not predictive of major cardiac
events, with the exception of the Duke score and the
exercise capacity, which only predicted events five years after
the test. The results of ST segment analysis were not
correlated with infarction-free survival. ST depression in
patients not reporting angina before the EXT was not
predictive of early revascularization. The predictive value of
the EXT is limited by the sensitivity and specificity of the
individual parameters and especially by the low incidence of
events (Table 7). Approximately nine in 10 patients with
low exercise tolerance and five in six patients with a
high-risk Duke score at one year will survive five years
(6,12,13). In this patient population, a more specific test,
such as radionuclide imaging or exercise echocardiography,
would still be expected to have a high incidence of false
positive results; only a fraction of those with a significant
perfusion defect will have a subsequent event.
These results in the context of plaque biology. Cardiac
events are caused by the transformation of stable plaques
to unstable plaques (14 –16). White et al. (17) showed
that, in over 50% of patients with an angiogram two
years before an MI, the ultimate culprit lesion was of
only borderline significance on the first study. An EXT
will only screen for coronary stenosis and cannot be
expected to predict which or whether plaques will become
Figure 2. Survival five years after the one-year exercise test (ET) in patients
with treated diabetes, by treatment allocation and exercise status. CABG 5
coronary artery bypass grafting; PTCA 5 percutaneous transluminal
coronary angioplasty.
Table 3. Combined Mortality or Myocardial Infarction Rates for the Two Years After the
Scheduled EXTs for the Test Takers and Non Test Takers
No EXT EXT RR
n KM% n KM% Univariate Multivariate*
1-year EXT 310 11.9 1,388 3.6† 3.70† 2.86†
3-year EXT 424 14.7 1,208 4.6† 3.26† 2.65†
5-year EXT 472 11.7 1,049 5.0† 2.08† 1.79‡
*Model includes age, gender, congestive heart failure, chronic obstructive pulmonary disease, peripheral vascular disease,
hypertension, history of myocardial infarction, treatment, diabetic status; †p , 0.0001; ‡p , 0.01.
EXT 5 exercise test; KM 5 Kaplan-Meier estimates; RR 5 relative risk.
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unstable. The most common symptom of progressive
disease is angina (18,19). Multiple studies have shown a
low incidence of cardiac events in stable patients after CR
without angina (18).
Routine ET one year after successful coronary revas-
cularization to identify patients at risk for subsequent
cardiac events presumes that the identification of stenosis
in patients with stable revascularized coronary disease
will be able to isolate patients at risk for events better
than a strategy of symptom-driven evaluation. Since the
important events, sudden death or infarctions, are infre-
quent in asymptomatic individuals, the best early detec-
tion strategy is not defined. The paradigm of aggressively
seeking out potential restenosis to revascularize the
stenotic vessel must be proven before being accepted as a
routine strategy (6,20).
Exercise testing in patients with diabetes. We did not
specifically evaluate individual exercise parameters in
patients with diabetes since the number of events and the
number of patients with diabetes who exercised was quite
small. However, the five-year mortality in treated pa-
tients with diabetes who did not exercise was quite
striking: 30% for patients undergoing CABG and 52.4%
for those undergoing PTCA. An examination of Figure 2
Table 4. Relationship Between Parameters Measured on Each EXT and the Univariate and Multivariate Risk Ratios for Survival for
the Two Years After the Test
Patients With EXT Univariate Model
Multivariate Model (Model
With CHF, Age, Gender,
Treatment, Diabetes,
Education, Diabetes-Treatment
Interaction)
p Value for
Overall Test of
EXT Variables
1-year EXT (n 5 1,388, 25 deaths) NS
Heart rate . 85% (220 2 age) RR 5 0.77 p 5 NS RR 5 0.69 p 5 NS
Systolic BP . 130 RR 5 0.24 p 5 0.0508 RR 5 0.77 p 5 NS
Stage 3 reached RR 5 0.75 p 5 NS RR 5 1.63 p 5 NS
Positive test (ST depression) RR 5 1.92 p 5 NS RR 5 2.09 p 5 0.09
3-year EXT (n 5 1,208, 43 deaths) 0.0732
Heart rate . 85% (220 2 age) RR 5 0.50 p 5 0.0261 RR 5 0.58 p 5 0.10
Systolic BP . 130 N/A N/A
Stage 3 reached RR 5 0.40 p 5 0.0040 RR 5 0.58 p 5 0.13
Positive test (ST depression) RR 5 0.85 p 5 NS RR 5 0.86 p 5 NS
5-year EXT (n 5 1,049, 54 deaths) 0.0334
Heart rate . 85% (220 2 age) RR 5 0.74 p 5 NS RR 5 0.91 p 5 NS
Systolic BP . 130 N/A N/A
Stage 3 reached RR 5 0.33 p 5 0.0001 RR 5 0.42 p , 0.0069
Positive test (ST depression) RR 5 0.87 p 5 NS RR 5 0.84 p 5 NS
NS 5 p . 0.10.
BP 5 blood pressure; CHF 5 congestive heart failure; EXT 5 exercise test; RR 5 relative risk.
Table 5. Relationship Between Parameters Measured on Each EXT and the Univariate and Multivariate Risk Ratios for Survival Free
of Myocardial Infarction for the Two Years After the Test
Patients With EXT Univariate Model
Multivariate Model (Model
With Age, Gender, CHF,
COPD, PVD, HTN, hx MI,
Treatment, Diabetes, Diabetes-
Treatment Interaction)
p Value for
Overall Test of
EXT Variables
1-year EXT (n 5 1,388, 48 events) 0.1700
Heart rate . 85% (220 2 age) RR 5 0.51 p 5 0.016 RR 5 0.58 p 5 0.0903
Systolic BP . 130 RR 5 0.30 p 5 0.0454 RR 5 0.65 p 5 NS
Stage 3 reached RR 5 0.70 p 5 0.1893 RR 5 1.57 p 5 NS
Positive test (ST depression) RR 5 1.59 p 5 0.1265 RR 5 1.65 p 5 0.1273
3-year EXT (n 5 1,208, 56 events) 0.1171
Heart rate . 85% (220 2 age) RR 5 0.51 p 5 0.0133 RR 5 0.68 p 5 NS
Systolic BP . 130 RR 5 0.69 p 5 NS RR 5 1.12 p 5 NS
Stage 3 reached RR 5 0.34 p 5 0.0002 RR 5 0.51 p 5 0.0372
Positive test (ST depression) RR 5 0.88 p 5 NS RR 5 1.05 p 5 NS
5-year EXT (n 5 1,049, 77 events) NS
Heart rate . 85% (220 2 age) RR 5 0.89 p 5 NS RR 5 0.98 p 5 NS
Systolic BP . 130 RR 5 0.79 p 5 NS RR 5 0.94 p 5 NS
Stage 3 reached RR 5 0.55 p 5 0.009 RR 5 0.70 p 5 0.184
Positive test (ST depression) RR 5 0.74 p 5 NS RR 5 0.75 p 5 NS
NS 5 p . 0.10.
BP 5 blood pressure; CHF 5 congestive heart failure; COPD 5 chronic obstructive pulmonary disease; EXT 5 exercise test; HTN 5 hypertension; hx MI 5 history of
myocardial infarction; PVD 5 peripheral vascular disease.
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shows a very limited mortality in the patients with
diabetes who exercised for the first year and a half after
the exercise test, so it seems also likely that exercise
parameters would be of limited value in these patients.
Study limitations. No additional imaging, echocardiogra-
phy or myocardial scintigraphy was used with the EXT
(21,22). Secondly, 7.8% of patients who experienced angina
on the EXT underwent revascularization within three
months of the study compared with 1.4% of those who did
not demonstrate angina. It is possible that the subsequent
procedures selected for patients with EXT abnormalities
attenuated a difference in cardiac events between the two
EXT groups. However, most of the patients undergoing
revascularization already reported angina at the time of the
test and were, therefore, not truly asymptomatic. Lastly,
these revascularizations were performed in 1988 through
1991, and considerable progress has occurred both in
revascularization techniques and management of coronary
disease itself, further lowering recurrence rates and making
prediction of recurrent events even more difficult and less
precise.
How does this relate to the ACC/AHA guidelines for
EXT in asymptomatic patients after coronary revascular-
ization? The ACC/AHA guidelines for EXT consider
EXT for prognosis in asymptomatic individuals for at least
three years after revascularization to be a class III indication,
i.e., the procedure is not useful and, in some cases, may be
harmful (1). Our data clearly support that position. The
ACC/AHA task force suggested that stress testing could
have a role for patients with particularly compelling anat-
omy, where the angioplastied lesion controls a large amount
of myocardium or where the patient clearly has a defective
warning system, i.e., when the patient suffers from silent
ischemia (1,4). We did not specifically evaluate these situ-
ations, and it is not clear whether the event rate is higher in
these patients.
Conclusions. The ability or willingness to take an EXT is
a simple, but powerful, discriminator of risk. In asymptom-
atic patients, the results of a routine (protocol driven) EXT
one year after revascularization does not reliably identify
those patients who will go on to have cardiac events in the
next year or two. However, it does delineate a small group
Figure 3. Survival six years after exercise test based on ability to exercise to Bruce Stage 3 (A) and on the Duke scores (B).
Table 6. The Number of Patients Revascularized Within 90 Days of the One-Year EXT
Segregated by Angina Reported Before the Test, Angina on the Test and ST Depression
Angina
Reported
Before the Test
Angina on
EXT
ST
Depression
Total
Number
Number
Revascularized
%
Revascularized
Yes Yes Yes 35 9 25.7%
Yes Yes No 46 0 0.0%
Yes No Yes 48 2 4.2%
Yes No No 126 6 4.8%
No Yes Yes 28 1 3.6%
No Yes No 19 0 0.0%
No No Yes 246 3 1.2%
No No No 839 7 0.8%
EXT 5 exercise test.
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at high risk within five years after the test. We found that
the best stratification occurred with recurrent evaluation for
the ability or willingness to exercise one, three and five years
after revascularization. Our findings are consistent with the
ACC/AHA guidelines on exercise testing suggesting no
role for routine exercise testing for at least three years after
successful coronary revascularization (1). These data suggest
that efforts to improve survival should be concentrated in
the patients who are not able to take the EXT.
Reprint requests and correspondence: Dr. Katherine Detre, c/o
BARI Coordinating Center, University of Pittsburgh, 127 Parran
Hall, 130 DeSoto Street, Pittsburgh, Pennsylvania 15261.
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